ISSN: 2529-9123

Clínica e Investigación en Arteriosclerosis is the official journal of the Spanish Society of Arteriosclerosis, the Latinoamerican Society of Arteriosclerosis and the Iberolatinoamerican Society of Arteriosclerosis. The journal is the leading Spanish written peer-review journal in the field of arteriosclerosis and its related risk factors. The aim of the journal is primarily the promotion of knowledge and continued medical education, with a special focus in the Spanish-speaking audience, through the publication of relevant research contributions, basic and clinical, in the field and the publication of review and update articles.

See more Open Access Option

Clínica e Investigación en Arteriosclerosis has received its first journal Impact Factor (JCR) in 2023. Instructions for authors - Submit an article

"Methodological Notes": a new and important section in Clínica e Investigación en Arteriosclerosis

Indexed in:

Web of Science, Index Medicus/MEDLINE, Scopus, IBECS, IME, MEDES

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

1.9

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.2

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.424

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.435

View more metrics

Journal Information

Back to article

Statistics

Follow this link to access the full text of the article

Original article

Thrombotic risk assessed by PAI-1 in patients with COVID-19: The influence of hyperglycemia and diabetes mellitus

Riesgo trombótico evaluado por PAI-1 en pacientes con COVID-19: la influencia de la hiperglucemia y la diabetes mellitus

Lourdes Basurtoa, Leticia Manuel-Apolinara,

Corresponding author

letymanu@yahoo.com.mx

Corresponding author.

, Ariadna Robledob, Sean O’Learyb, Carlos Martínez-Murilloc, Lina Ivette Medina-Ortíza, Mario German Montes Osoriod, Julio Zarazuaa, Lourdes Balcázar-Hernándeze, Juan Carlos Anda-Garayf

a Endocrine Research Unit, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtémoc 330, Doctores, CP 06720 Mexico City, Mexico

b Department of Neurosurgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA

c Hematology Department, Hospital General de México, Dr. Balmis 148, Doctores, Cuauhtemoc, 06720 Mexico City, Mexico

d Nuclear Medicine Department, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtémoc 330, Doctores, CP 06720 Mexico City, Mexico

e Endocrinology Department, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtémoc 330, Doctores, CP 06720 Mexico City, Mexico

f Internal Medicine Department, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Av. Cuauhtémoc 330, Doctores, CP 06720 Mexico City, Mexico

Read

Times
was read the article

Total PDF

Total HTML

Share statistics

Article information

ISSN: 25299123
Original language: English

DOI:10.1016/j.artere.2024.07.007

The statistics are updated each day